Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, Gill S, Peter A, Talbot S, Tohumeken S, Fryer H, Mostafa A, Mulgrew K, Lam C, Hoffmann S, Sutton D, Carnevalli L, Calero-Nieto FJ, Jones GN, Pierce AJ, Wilson Z, Campbell D, Nyoni L, Martins CP, Baker T, Serrano de Almeida G, Ramlaoui Z, Bidar A, Phillips B, Boland J, Iyer S, Barrett JC, Loembé AB, Fuchs SY, Duvvuri U, Lou PJ, Nance MA, Gomez Roca CA, Cadogan E, Critichlow SE, Fawell S, Cobbold M, Dean E, Valge-Archer V, Lau A, Gabrilovich DI, Barry ST. Hardaker EL, et al. Among authors: talbot s. Nat Commun. 2024 Feb 24;15(1):1700. doi: 10.1038/s41467-024-45996-4. Nat Commun. 2024. PMID: 38402224 Free PMC article.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: talbot s. NPJ Breast Cancer. 2023 Aug 5;9(1):64. doi: 10.1038/s41523-023-00571-w. NPJ Breast Cancer. 2023. PMID: 37543694 Free PMC article.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, DeBruin E, Barry ST. Hopcroft L, et al. Among authors: talbot s. NPJ Breast Cancer. 2023 Aug 18;9(1):69. doi: 10.1038/s41523-023-00575-6. NPJ Breast Cancer. 2023. PMID: 37596288 Free PMC article. No abstract available.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: talbot s. NPJ Breast Cancer. 2023 Sep 19;9(1):76. doi: 10.1038/s41523-023-00581-8. NPJ Breast Cancer. 2023. PMID: 37726304 Free PMC article. No abstract available.
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.
Bertran-Alamillo J, Giménez-Capitán A, Román R, Talbot S, Whiteley R, Floc'h N, Martínez-Pérez E, Martin MJ, Smith PD, Sullivan I, Terp MG, Saeh J, Marino-Buslje C, Fabbri G, Guo G, Xu M, Tornador C, Aguilar-Hernández A, Reguart N, Ditzel HJ, Martínez-Bueno A, Nabau-Moretó N, Gascó A, Rosell R, Pease JE, Polanska UM, Travers J, Urosevic J, Molina-Vila MA. Bertran-Alamillo J, et al. Among authors: talbot s. Mol Cancer. 2023 Jul 13;22(1):110. doi: 10.1186/s12943-023-01815-w. Mol Cancer. 2023. PMID: 37443114 Free PMC article.
Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.
Pfeifer M, Brammeld JS, Price S, Pilling J, Bhavsar D, Farcas A, Bateson J, Sundarrajan A, Miragaia RJ, Guan N, Arnold S, Tariq L, Grondine M, Talbot S, Guerriero ML, O'Neill DJ, Young J, Company C, Dunn S, Thorpe H, Martin MJ, Maratea K, Barrell D, Ahdesmaki M, Mettetal JT; Functional Genomics Centre; Brownell J, McDermott U. Pfeifer M, et al. Among authors: talbot s. Commun Biol. 2024 Apr 24;7(1):497. doi: 10.1038/s42003-024-06190-w. Commun Biol. 2024. PMID: 38658677 Free PMC article.
Where east meets west: Phylogeography of the high Arctic North American brant goose.
Wilson RE, Boyd WS, Sonsthagen SA, Ward DH, Clausen P, Dickson KM, Ebbinge BS, Gudmundsson GA, Sage GK, Rearick JR, Derksen DV, Talbot SL. Wilson RE, et al. Among authors: talbot sl. Ecol Evol. 2024 Apr 10;14(4):e11245. doi: 10.1002/ece3.11245. eCollection 2024 Apr. Ecol Evol. 2024. PMID: 38601857 Free PMC article.
Next Directions in the Neuroscience of Cancers Arising outside the CNS.
Amit M, Anastasaki C, Dantzer R, Demir IE, Deneen B, Dixon KO, Egeblad M, Gibson EM, Hervey-Jumper SL, Hondermarck H, Magnon C, Monje M, Na'ara S, Pan Y, Repasky EA, Scheff NN, Sloan EK, Talbot S, Tracey KJ, Trotman LC, Valiente M, Van Aelst L, Venkataramani V, Venkatesh HS, Vermeer PD, Winkler F, Wong RJ, Gutmann DH, Borniger JC. Amit M, et al. Among authors: talbot s. Cancer Discov. 2024 Apr 4;14(4):669-673. doi: 10.1158/2159-8290.CD-23-1495. Cancer Discov. 2024. PMID: 38571430
545 results